Rationale and study design for the first precision medicine randomized placebo-controlled trial in the 16p11.2 deletion syndrome

This is a Pre-Registered Trial study.

Key Points

Evaluate the effectiveness of precision medicine in treating 16p11.2 deletion syndrome through a randomized controlled trial.
Randomized, double-blind, placebo-controlled trial design
Investigating participants with 16p11.2 deletion syndrome
Comparing outcomes between intervention group and placebo group
Trial aims to demonstrate benefits of precision medicine
Expectation of improved outcomes in patients with 16p11.2 deletion syndrome

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Randomized trial tests precision medicine in 16p11.2 deletion syndrome, suggesting potential for effective treatment.

Nct04271332; 2020-02-13.

No takes yet. Share an insight, caveat, or question.

Rea et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share